MedTrace Logo

(TNX-1500) in Kidney Transplant Recipients

NCT07204080 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2026-02-25

No results posted yet for this study

Summary

The primary objective is to investigate the safety and efficacy of TNX-1500, an FC-modified anti-CD154 mAb, in five kidney transplant recipients at 12 months.

Conditions

  • Kidney Transplant
  • Kidney Transplant Failure and Rejection
  • Immunosuppression
  • Immunosuppression After Kidney Transplantation

Interventions

DRUG

TNX-1500

This is an open-label, single-center, single-arm study to assess the safety and efficacy of TNX-1500, an Fc-modified anti-DF154 mAb in five adult kidney transplant recipients.

PROCEDURE

Kidney Transplant

Kidney Transplant

Sponsors & Collaborators

  • Tonix Pharmaceuticals, Inc.

    collaborator INDUSTRY

  • Ayman Al Jurdi, MD

    lead OTHER

Principal Investigators

  • Ayman Al Jurdi, MD · Massachusetts General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-01
Primary Completion
2028-09-01
Completion
2029-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07204080 on ClinicalTrials.gov